Eiger BioPharmaceuticals, Inc. (EIGR) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Palo Alto, CA, 美国. 现任CEO为 David Apelian.
EIGR 拥有 IPO日期为 2014-01-30, 56 名全职员工, 在 NASDAQ Global Market, 市值为 $2.55M.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
